VIRUS INACTIVATED BLOOD PRODUCT AND METHOD

Abstract: The treatment of blood product to inactivate or destroy infective viruses found in animal fluids and tissues, such as the cytomegalovirus, by mixing the blood product with an effective amount of glycyrrhizic triterpenoid compounds in combination with albumin is disclosed.

Description: VIRUS INACTIVATED BLOOD PRODUCT AND METHOD Field of the Invention This invention relates to the treatment of transfusion blood and blood products for use in transfusion therapy with one or more of a class of compounds referred to here as glycyrrhizic compounds, exemplary of which are glycyrrhizin, glycyrrhizinic acid or glycyrrhetinic acid glycoside, and analogous triterpenes, e.g. carbenoxolone and cicloxolone and their derivatives in combination with albumin, to inactivate virus found in animal fluids and tissues, such as cytomegalovirus, bovine diarrhea virus, human immunodeficiency virus and hepatitis viruses. Background of the Invention This invention relates to the treatment of transfusion blood and transfusion blood products to inactivate or destroy infective viruses found in animal fluids and tissues, such as the cytomegalovirus which is responsible for or aggravates serious and sometimes fatal infections, in blood transfusion recipients. Cytomegalovirus (CMV) is probably the most ubiquitous of the pathogenic viruses found in animal fluids and tissues. Virtually all of the people living in the developing countries become infected with CMV early in life, and CMV infects over half the population in the developed countries of the world. CMV may remain essentially inactive in the body following an initial infection and may flare in to an active infection any time, most frequently when the body's immune system is compromised to a greater or lesser degree by disease, radiation therapy, drug therapy, surgical trauma, etc. CMV is frequently associated with, and may be a causative or contributing factor in, life-threatening disease in individuals with suppressed immune systems, and can be a principal causative factor in pneumonia, neurological disorders, febrile illness, ocular disease and hepatitis. CMV infection is a serious limiting factor in the transplantation of organs, tissues and cells and the transfusion of blood and plasma from one individual to another. The kidney transplant patient xuns a high risk of contracting serious, and not infrequently fatal, CMV infection from CMV introduced by the transplant organ. Recipients of whole blood, plasma, bone marrow, cornea, cardiac, and semen run a serious risk of CMV infectious disease, the risk being multiplied where the immune system of the recipient is suppressed to prevent rejection of the foreign organ or cells, or where immunosuppression is present from natural causes. CMV is frequently associated with Pnewnonc stis carinii and may cause or contribute to encephalitis and colitis and may be associated with Kaposi's sarcoma in AIDS patients. CMV is so ubiquitous in the blood and organs of donors who, frequently, exhibit no symptoms of infection, and its direct and contributory effects in infectious diseases is so pervasive and subtle that a CMV infection is to be presumed if another causative agent cannot be established. There are no proven cures or generally effective drugs for the treatment of CMV infections. Certain drugs, e.g. ganciclovir, has been shown to have limited effectiveness in the treatment of certain CMV infections, e.g. CMV retinitis, but has little effect in the treatment of CMV pneumonia. Live attenuated CMV vaccine has been developed but may not protect against infection by natural CMV, and there is a real risk that the attenuated CMV may reactivate during pregnancy and infect the fetus. While a method of preventing, or even reducing the likelihood of transmitting CMV via transfusion or transplant of organs, tissues, cells or fluids would be of enormous benefit to medical science, the present invention is not limited to treatments to inhibit CMV infection and is applicable to other classes of viruses found in animal fluids and tissues. CMV is a member of the human herpesvirus (HV) group, which are responsible for much of mankind's discomfort and pain. The herpesviruses represent a very large, clearly defined group of viruses which are responsible for, or involved in, cold sores, shingles, a venereal disease, mononucleosis, eye infections, birth defects and probably several cancers. Three subfamilies are of particular importance. The alpha subfamily includes HV-1 (herpes virus simplex 1) which causes cold sores, fever blisters, eye and brain infections, HV-2 (herpes virus simplex 2) which cause genital ulceration, and HV-3 (HV varicella zoster) which causes chicken pox, shingles and brain infections. The beta subfamily includes HV-5 , the principal member of which is CMV discussed above. The gamma subfamily includes HV-4 (Epstein- Barr) which cause infectious mononucleosis and is involved in Burkitt's lymphoma and nasopharyngeal carcinoma. Additional possibly pathogenic herpes viruses no doubt exist, one type of which, HV-6, of unknown pathogenicity has been identified. (Niederman, J. C. et al., The Lancet, Oct. 8, 1988, 817). There is evidence that the methods of this invention are effective in inhibiting the transmission of infections caused by many and perhaps all of the pathogenic herpes viruses found in animal fluids and tissues. While blood bankers have instituted rigid criteria for exclusion of potential donors in high risk categories, this is not a satisfactory solution to the most significant threat to face the health care community in many decades. Institution of human immunodeficiency virus (HIV) testing has blood products safer, but the complete elimination of HTV contaminated blood and blood products has not been possible using present knowledge and technology. The ELISA test, for example, misses approximately 1 in 200 (0.5 %) HTV infected donors, and there is no certain method for excluding donor carriers of hepatitis and other infectious viruses found in animal fluids and tissues. Increasing efforts are exerted to improve the safety of the blood supply such as retrovirus screening using surrogate markers, screening for HIV and other retroviruses with attention to population surveillance for newer agents, cleaner methods of extracting specific blood components by monoclonal antibody techniques and DNA methodologies, development of recombinant DNA products which by-pass the need for plasma derived clotting factors for administration to hemophiliacs. Careful screening of donors, followed by antibody testing, reduces the risk of AIDS and other virus-contaminated blood, but such methods are not foolproof. Such methods require testing supplies and trained technicians which are not available and are too expensive for use in such places as central Africa and other third-world countries where AIDS infects up to one-third of the population. A simpler and less costly method of handling blood is required in such areas of the world. A photodynamic method has also been evaluated as a means of eradicating viral contaminants (Matthews, J. L. et al., Transfusion, 28,1 1988) but has not been proved to be generally effective and safe. While Factor VQI products may be rendered non-infectious by heat or solvent- detergent methods, no methods are known to guarantee the safety of whole blood or cellular components or plasma. For the whole blood recipient, however, the only reasonably reliable safety procedures are programs allowing for self donation prior to elective surgery by the donor and the use of blood from designated donors, but such programs are incredibly difficult logistically. In spite of heroic efforts to meet the challenge of virus contami- nated blood supply, an imperative need continues to exist for a method for treating whole blood for use in transfusion. It is apparent from the foregoing discussion that a method of killing or inactivating pathogenic viruses in organs, tissues, cell and fluids intended for transfusion or transplantation would be an enormous advance in medicine. It is to this major national and worldwide health care challenge that the present invention is directed. Glycyrrhizic acid, 20B-carboxy-ll-oxo-30-norolean-12-en-3B-yl-2- O-B-D-glucopyranuronsyl-α-D-glucopyranosiduronicacid, commonly known as glycyrrhizin, glycyrrhizinic acid or glycyrrhetinic acid glycoside (also referred to as biosone, enoxolone, and glycyrrhetin) an extract from Glycyrrhiza, better known as licorice, an extract of the dried rhizome and roots of Glycyrrhiza glabra, is a triterpene and is exemplary of the triterpenes to which this invention relates. Analogous triterpenes to which this invention relates include carbenoxolone and cicloxolone. This invention thus relates to glycyrrhizic acid and analogues thereof, in the form of acids, salts, esters and other derivatives. Many such derivatives are known, such as, for example, glycyrrhetinyl stearate; monopotassium glycyrrhetin; potassium glycyr- rhetinate; 11-deoxoglycyrrhetinic acid hydrogen maleate sodium salt; α- D-glucopyranosiduronic acid monoarginine glycyrrhizinate; 18α-Glycyrrhizic acid monosodium salt; 18-α-Glycyrrhizic acid monopotassium salt; disodium 18-α-glycyrrhizate; glycyrrhizinic acid mono(triethanolamine) salt; trisodium glycyrrhizinate; sodium glycyrrhizate; ammonium glycyrrhizinate; sodium carbenoxolone (biogastrone; glycyrrhetinic acid hydrogen succinate disodium salt); and acetylglycyrrhetic acid (glycyrrhetinyl acetate). Glycyrrhizin and the virucidal analogues and derivatives thereof are referred to for convenience herein as glycyrrhizic triterpenoids abbreviated GTPD. Presently the principal GTPD compounds of interest are glycyrrhizin (coded TPD-1 in some of my work), carbenoxolone (coded TPD-2 in some of my work) and cicloxolone. Ring-substituted derivatives of GTPD compounds are contemplated and are included in this invention. Halogen ring substituents, such as, for example, fluoro- and chloro- substituents, sulfate and other active and/or inactivating substituents to the ring structure of GTPD compounds are specifically included in this invention, without excluding other ring-substituted derivatives of GTPD compounds. In addition to its use as a flavoring agent, licorice has long been a common folk medicine for the treatment of sore throats. While not widely known, various extracts of and preparations derived from licorice, e.g. glycyrrhizin and its derivatives, principally the salts of glycyrrhizic acid, have also been used to a limited degree for many years as an orally administered medication for the treatment of peptic ulcers (Chandler, R. F., Can. Pharm. J. , VI 18, No.9, 1985), and oral administration of glycyrrhizin contempora¬ neously with saponin antiinflamatory agents has been reported to inhibit saponin and saponigen heπaolysis (Segal, R. et al., Biochem. Pharmacol. 26, 7 1977). GTPDs have been evaluated extensively in vitro, and have been administered orally, intramuscularly and intravenously. No significant toxicity from limited, short term administration of glycyrrhizin has been reported. Adverse reactions have been reported in certain instances of prolonged oral ingestion and a slight relapse after rapid discontinuation of intravenous administration of Stronger Neo-Minaphagen C (SNMC) solution, glycyrrhizin (0.2%), cysteine(0.1%) and glycine (2%) was attributed to the steroid ring in glycyrrhizin (Fujisawa K. et al. , Asian Med. J. (Japan), 23, 10 1980) . Dosages of SNMC as high as 60 ml/day (~ 12 mg/dy of glycyrrhizin) have been reported (Iwamura K., Therapiewoche (W. Germany) 30,34 1980). Inactivation of viruses, in vitro, under certain conditions, has been reported (see, e.g., Pompei R., Exprientia (Switzerland) 36/3 1980). Such anti-viral activity as GTPD compounds sometimes exhibit has been attributed to reverse transcriptase-inhibitory activity (Nakashima, H. et al., Jpn. J. Cancer. Res. 78,8 1987) and to enhancement of interferon-gamma production (Shinada, M. et al., Proc. Soc. Exp. Biol. 181,2 1986), but the exact mechanism of the anti-viral function has not been confirmed. Dargan, D. J., and Subak-Sharpe, J. H., ( J. Gen. Virol., 1985- 1986) reported antiviral action of carbenoxolone and cicloxolone on herpes simplex virus. Their dose-response experiments showed cicloxolone sodium or carbenoxolone sodium interfered with the HSV replication cycle and jeduced the infectious virus yield by 10,000- to 100,000-fold, cicloxolone being the more potent anti-herpes agent, but no consistent effect on HSV DNA synthesis was identified. Some inhibition of cellular DNA synthesis was observed, but this was relatively slight. Csonka, G. W. and Tyrrell, D. A. (Br. J. Verier. Dis. 1984, 60 (3) pl78) undertook a double blind clinical study to compare the efficacy of carbenoxolone and cicloxolone creams with placebo in initial and recurrent herpes genitalis and reported significant differences in the time to disappear¬ ance of pain and the healing of lesions using cicloxolone, but carbenoxolone showed insignificant beneficial effect. GTPDs have also been evaluated therapeutically as anti-viral agents in the chemotherapy of acquired immune deficiency syndrome (AIDS) (Ito, M. , Yamamoto, N., Yakaguaku Zasshi (Japan) 188,2 1988), treatment of Epstein-Barr virus (EBV) infections (Van Benschoten, M. M., Am. J. Acupunct, 16,1 1988), and in the treatment of chronic hepatitis (Fujisawa, K. et al., Asian Med. J. (Japan), 23,10 1980). The anti-viral activity of GTPDs varies so unpredictably as to preclude any generalized statements as to whether such compounds have general anti¬ viral effect or even as to whether such compounds will generally have anti¬ viral value as to any given virus. While GTPD drugs do, in some environ¬ ments and under some conditions, exhibit some activity against some viruses, no anti-viral therapy based on GTPDs or in vitro anti-viral application of GTPDs has been generally accepted. The AIDS-causing viruses, HIV-I and HTV-II, are the first retroviruses identified as pathogenic in man. While HIV are more fragile than most infectious viruses and are susceptible to destruction by most virus-inactivating methods, such as heating, use of detergent compounds, etc., these methods also damage cells, e.g. the red blood cells, and, therefore, are not suitable for use in treating blood. In addition, any substance added to blood will, unless removed, remain in the blood, and must, therefore, be non-toxic when administered intravenously. Removal of added toxins from blood is, at best, complex and expensive and may not be feasible or possible without serious damage to blood components. The major constituent of plasma is albumin whose primary role is that of osmotic regulation; it is responsible for 75-80% of the osmotic pressure of plasma. Albumin also serves important roles in the transport of small molecules such as drugs. An important feature which segregates albumin from other colloids as well as crystalloids is its unique ability to bind reversibly with both anions and cations; hence, albumin can transport a number of substances including fatty acids, hormones, enzymes, dyes, trace metals, and drugs. Substances which are toxic in the unbound or free state are generally not toxic when bound to albumin. This binding property also enables albumin to regulate the extracellular concentration of numerous endogenous as well as exogenously administered substances. Albumin in general has three types of binding sites (one for acidic, one for basic, and one for neutral compounds), and it plays a critical role in the binding and transport of lipid and lipid-soluble material. Albumin binds with and transports many administered drugs. Because of the phenomenon of mutual displacement of similar type substances, adverse drug interactions may occur. This phenomenon may have important ramifications during disease states such as sepsis, burn injury, and circulatory shock due to a number of etiologies, especially in conjunction with treatment with drugs which may be toxic at high concentrations. Treatment with human serum albumin to bind toxic products generated during inflammatory disease states has not received widespread attention. However, a few studies and the inherent ability of -albumin to bind with numerous toxic plasma substances support the concept. Albumin is critical for the transport of numerous compounds, especially non-water soluble ones. It binds with iron and lipϊds and other potentially toxic substances, e.g., bilirubin. Thus albumin acts as a buffer to prevent increases in potentially cytotoxic endogenous lipid-soluble substances by binding with, and thus limiting, increases in plasma and interstitial fluid concentrations of these substances. In addition to displacement of on albumin-bound drug by another, endogenous substances may also alter significantly the unbound or "free" plasma and interstitial fluid concentration of a drug. For example, as the concentration of bilirubin increases in certain disease states, a drug which occupies the same binding site as bilirubin will be displaced by the bilirubin, and the plasma concentration of the free drug will increase, possibly to toxic levels. Also, as the plasma concentration of albumin decreases, the plasma and interstitial fluid concentration of the unbound (free) drug will increase. Plasma albumin concentration is usually decreased to varying degrees in disease states such as sepsis, burn injury, and circulatory shock. Resuscitation with large volumes of non-albumin colloid or crystalloid solutions will further decrease an already low albumin concentration and may consequently further limit the ability of albumin to modulate the free concentration and transport of toxic substances or drugs administered for therapeutic purposes. Another feature of albumin is its inhibitory effect on pathologic platelet aggregation, which may be due to a greater affinity of arachidonic acid for albumin than for platelet-generated cyclooxygenase. It has also been demonstrated that albumin enhances the inhibition of factor Xa by antithrom- bin-m (AT-m). In addition to the well-known role of albumin in generating colloid osmotic pressure, it also may protect the lung and other organs from edema by preserving microvascular integrity. Very recent work support a role for albumin in the maintenance of normal microvascular permeability to protein. It is known that albumin binds to glycyrrhizic triterpenoids. Carben¬ oxolone is a potent ulcer-healing drug which is extensively bound to plasma proteins and therefore has the potential for displacement interaction. Carben¬ oxolone has been shown to be bound to human serum albumin in vitro at a different class of binding site to many other drugs and does not potentiate the pharmacological activity of warfarin, tolbutamide, chlorpropamide or phenytoin in the rat. Thornton PC; Papouchado M; Reed PI Scand J Gastroenterol Suppl 1980, 65 p35-9 The binding of glycyrrhizin to human serum and human serum albumin (HSA) was examined by an ultrafiltration technique. Specific and nonspecific bindings were observed in both human serum and HSA. The association constants (K) for the specific bindings were very similar: 1.31 x 10 5 M "1 in human serum and 3.87 x 105 M "1 in HSA. Glycyrrhizin binds to only the albumin fraction. It was concluded that the glycyrrhizin-binding sites in human serum exist mainly on albumin and glycyrrhizin binds to specific and nonspecific binding sites at lower and higher concentrations than approximately 2 mM, respectively. Ishida S; Sakiya Y; Ichikawa T; Kinoshita M; Awazu S , Chem Pharm Bull (Tokyo) 37 (1). 1989. 226-228. Comparison by equilibrium dialysis of plasma protein binding sites for carbenoxolone in people under 40 yr of age and in people over 65 yr of age showed that the number of binding sites was reduced in the elderly and that this fall was associated with a reduction in plasma albumin levels. Hayes M J; Sprackling M; Langman M, Gut 18 (12) 1977 1054-1058. Albumin has been used as an emulsion stabilizer oil-and-water emulsion injectable medical preparations, e.g. fluorbiprofen, Mizushima et al, U.S. Patent 4,613,505, Sept. 23, 1966; as a binding molecule for tryptophan, Pollack, U.S. Patent No. 4,650,789, Mar. 17, 1987; with chemical modification as complexing agents for cholesterol derivatives, Arakawa, U.S. Patent No. 4,442,037, Apr. 10, 1984; as conjugates with enzyme chemically linked to an antibody, Poznansky, U.S. Patent No. 4,749,570, June 7, 1988; and as chemically coupled conjugates of leuko- trienes, Young, et al, U.S. Patent No. 4,767,745, Aug. 30, 1988. The safest source of albumin, in many instances, is the patient's own blood, and it is known to remove the blood, accomplish a partial fractionation of the blood, treat one fraction of the blood and return the treated fraction to the patient. Ishizaki et al, U.S. Patent No. 4839055, June 13, 1989, describe a method for treating a blood which involves separating the blood withdrawn from a patient's body, mixing the condensed blood and the low molecular weight protein with a substitute liquid and returning the combined liquid into the patient's body. It was discovered that glycyrrhizin, glycyrrhetinic acid, carbenoxolone and cicloxolone and the analogues thereof (glycyrrhizic triterpenoids or GTPD compounds) not only inactivate HIV in blood and are known to be well- tolerated intravenously but, in some instances, also serve as effective anticoagulants and cell-stabilizers and do not interfere with standard blood analyses. Summary of the Invention It has now been discovered that albumin binding to GTPD (glycyrrhi¬ zin, glycyrrhetinic acid, carbenoxolone and cicloxolone and the analogues thereof) does not reduce, and generally to enhances, the viral inactivation power of GTPD, and eliminate at low concentrations or greatly reduce any tendency of GTPD to hemolyze red blood cells. These discoveries are of enormous import, e.g. meaning, inter alia that GTPD can be carried into the system via albumin without losing its viral inhibition power, can be used at much higher concentrations than would otherwise be possible, and can be used where hemolysis is unacceptable. It has now been discovered that combinations of GTPD compounds with albumin (GTPD-Albumin) exhibit striking and most unexpected advantages in viral inactivation. Viral inactivation, as used here, means rendering the virus non- infective, i.e. the virus does not induce disease in a patient. In most instances traditional methods of quantifying virus population growth and reduction, e.g. log kill (See Fraenkel-Conrat, H., Kimball, P.C., and Levy, J.A. VIROLO¬ GY, Second Edition, Prentice Hall, Englewood Cliffs, N.J., 1988, and Jakoby, W. H. and Pastan, I. H. (Eds), CELL CULTURE, (Volume LVIII of "Methods in Enzymology " , Academic Press, Inc. , New York, Chapter 11) are good indicators of viral inactivation. However, viral inactivation is accomplished by GTPD-Albumin beyond the log kill measurement since any remaining virus are incapable of infecting a patient and are incapable of replicating. At least one of the retroviridae is susceptible to the treatment of this invention, according to presently available data. The most notorious of the retroviridae, HTV-1, the only virus thus far identified as inducing ADDS in humans, is inactivated and/or killed using the methods and compositions of this invention. Other retroviridae are considered to be susceptible to the present invention, and treatment to prevent transmission of retrovirus- infected organs, tissues, cells and fluids is within the scope of this invention. The present invention comprises methods for inactivating viruses in whole blood by the use of extracts of the well-known flavoring agent licorice, referred to here as glycyrrhizic triterpenoids or GTPD compounds in combination with albumin, GTPD-Albumin. This invention relates to methods for collecting and treating whole blood with GTPD compounds, e.g. glycyrrhizic acid, its analogues such as carbenoxolone and cicloxolone, analogues thereof and the salts, esters and other derivatives thereof in combination with albumin, GTPD-Albumin, as an viral inactivation enhancing agent, and to whole blood for transfusion containing such compounds which is free of CMV virus capable of infecting the recipient of such blood. Inactivation of other viruses found in animal fluids and tissues also results. This invention is embodied in the process of collecting blood from a donor comprising withdrawing the blood from the donor and introducing the blood into a whole blood container which contains an effective amount of a GTPD compound consisting essentially of glycyrrhizin, glycyrrhetinic acid, carbenoxolone, cicloxolone and analogues and derivatives thereof, or mixtures thereof in combination with albumin, GTPD-Albumin, as an viral inactivation enhancing agent for inactivating HIV and other viruses found in animal fluids and tissues and preventing coagulation of the collected blood. This invention is also embodied in commercial blood containers which comprise an amount of a GTPD compound which consists essentially of glycyrrhizin, glycyrrhetinic acid, carbenoxolone, cicloxolone analogues and derivatives thereof, or mixtures thereof in combination with albumin, GTPD- Albumin, as an viral inactivation enhancing agent in an amount effective to inactivate HIV and/or other. The GTPD compound may advantageously be used in combination with a viral inactivation enhancer, e.g. glycerol or EDTA, or both, of the contents of the improved container when full of the blood produces), sufficient to substantially inactivate viruses contained in the blood product introduced into said improved container. There is a striking synergism between the glycerol and the glycyrrhizic triterpenoid compound(s) rendering the combination surprisingly effective in inactivating susceptible viruses which may be in the blood product. Even such trace amounts of glycerol as would be ineffective as viral inactivator constitutes in blood products enhance the viral inactivation value of GTPD many fold. Many blood containers have a large compartment for receiving the blood product and one or more side pouches or side containers which have a wall or a closure which, by appropriate physical manipulation, can be opened or ruptured to introduce the contents thereof into the large compartment. Obviously, the nature of the container is immaterial so long as the end result, i.e. a container full of blood product containing the GTPD, can be accom¬ plished with the container. Thus, the invention is embodied in a transfusion blood container for the introduction of one or more blood products, such as whole blood, platelet concentrations, leukocyte concentrations, plasma, plasma derivatives, whole blood fractions, and combinations thereof, for transfusing the patient, the invention comprising a transfusion blood container and an amount of one or more glycyrrhizic triterpenoid compounds sufficient to comprise from 0.05 to 10.0 wt/%, preferably from about 0.5 to about 3 wt/%, of the contents of the improved container when full of the blood product(s), sufficient to substantially inactivate viruses contained in the blood product introduced into said improved container. The GTPD may be combined with a viral inactivation enhancer, e.g. glycerol or EDTA, or both, in concentrations of from approximately 0.0001 to 5 wt/%, of the contents of the improved container when full of the blood product(s), sufficient to substantially inactivate viruses contained in the blood product introduced into said improved container. There is a striking synergism between the glycerol and the glycyrrhizic triterpenoid compound(s) rendering the combination surprisingly effective in inactivating susceptible viruses which may be in the blood product. Even such trace amounts of glycerol as would be ineffective as viral inactivator constitutes in blood products enhance the viral inactivation value of GTPD ' many fold. There is a striking synergism between the glycerol and the glycyrrhizic triterpenoid compound(s) rendering the combination surprisingly effective in inactivating susceptible viruses which may be in the blood product. Even such trace amounts of glycerol as would be ineffective as viral inactivator constitutes in blood products enhance the viral inactivation value of GTPD many fold, of the contents of the container when full of the blood product(s) , sufficient to substantially inactivate viruses contained in the blood product introduced into said container. Description of the Preferred Embodiment The preferred method of carrying out the invention comprises providing a transfusion blood container which comprises an amount of the GTPD compound, e.g. glycyrrhizin, glycyrrhetinic acid, carbenoxolone or cicloxolone in combination with albumin, GTPD-Albumin, sufficient to inactivate CMV and/or other viruses in blood collected therein from a donor such that the GTPD comprises from about 0.001 weight percent (w/%) to about 10 w/%, generally in the range of about 0.05 to about 3 w/%, of the collected blood when the container is filled. The collected blood is held at normal room temperatures, or preferably at about 37°C. ± about 8°C, or for a longer period of time near 0°C, generally from about one hour to as much as twenty four hours or more to assure viral inactivation. Longer holding periods are equivalent in all essential respects with no significantly improved results. The holding period may be, and preferably is, immediately after collection, but may be at any stage in handling or processing. A holding period of from one-fourth hour to one hour at 45°C. is normally sufficient to assure that CMV and other blood borne viruses are inactivated. An overnight holding period, 12 to 24 hours, is sufficient even at lower temperatures. Careful mixing is desirable and is preferably conducted immediately after the first mixing of blood and GTPD-albumin mixture. Delipidated albumin from any source which is safe for intravenous use may be used to form GTPD-Albumin for use in this invention. Delipidated conventional caprylate stabilized, heat treated albumin may be used, for example. GTPD-Albumin is prepared simply by mixing GTPD into an albumin solution and allowing the solution to equilibrate a sufficient period of time, a few minutes being sufficient, to assure homogeneity and the formation of GTPD-Albumin. It is convenient to form a saturated solution of GTPD-Albumin, allow it to stand overnight and, if necessary, to filter the solution to assure that any excess GTPD or any precipitate is removed, and then to dilute the GTPD-Albumin solution as desired, or use it full-strength as an additive to blood products. In appropriate instances, the patient's own albumin may be used. If, for example, it is known sufficiently in advance that a patient will be receiving whole blood or a blood product, and if the patient's health permits, an appropriate amount of the patient's blood may be taken and fractionated sufficient to provide a fraction which does not contain red blood cells, contains the albumin, preferably delipidated albumin, of the patient. GTPD is then mixed into the delipidated albumin-containing fraction and the GTPD- Albumin is allowed to form by letting the mixture stand for a few minutes to a few hours. Prolonged standing or storage, e.g. several days to a few weeks, is not detrimental. The GTPD-Albumin is then mixed with the blood and the resulting blood (or blood product) mixture is maintained at a suitable temperature long enough, as discussed above, to inactivate the virus which may be in the blood product. For example, GTPD-Albumin may be prepared the day preceding or a few hours before elective surgery using the patient's own delipidated albumin. The GTPD-Albumin is mixed with the transfusion blood product about an hour before expected use thereof and the GTPD- Albumin - blood product mixture is maintained at about 37°C. ± about 8°C. for an hour or more and the virus-inactivated blood product is used to transfuse the patient. Particularly striking results are accomplished using delipidated albumin which has not been stabilized in the traditional way, e.g. with caprylate, and has not been heated. According to the prior art, such an delipidated albumin product would be regarded as unsafe because of the potential presence of pathogenic virus. If, however, the stabilization step and the heating step are replaced by the addition of GTPD to the delipidated albumin, the virus are inactivated and the delipidated albumin is biologically competent. GTPD- Albumin formed in this manner has higher biological activity than GTPD- Albumin prepared from conventional delipidated albumin. In a test using a VSV/BVD sensitive cell line performed when the cells were in log phase, the samples were inoculated with 10 9 pfu of vesicular stomatitis virus (VSV), incubated overnight and serially diluted in MEM with 10 % FBS (fetal bovine serum), and then inoculated with VSV. The 0.10% GTPD (carbenoxolone) alone and 0.10% GTPD (carbenoxolone) in 5% solutions of various albumins were introduced at dilutions of from 1: 10 2 to 1: 10 9 . The cells were examined daily for five days for virus caused CPE. following table summarizes the comparative results. LOG KILL OF VSV BY TPD Log Kill Albumin Used Five Days None 4.6 Baxter Buminate ® (USP Lot 2746M0I1AA) 1.3 Miles Human Albumin Fatty Acid Free (Lot 82-324) 1.6 Hyland IS 9988 Human Albumin 2.0 Non-Stabilized, solvent detergent albumin 0 ' 5.6+ (1) Huma serum albumin prepared by Conn Fractionation, Solvent-Detergent precipitation and alcohol ultrafiltration, not heated and no stabilizer, e.g. caprylate or tryptophan added. It should be noted that at extreme dilutions of GTPD, binding to albumin may actually reduce antiviral activity; however, higher concentrations of GTPD can be used and the viral inactivation is not decreased even with the least biologically competent albumin and enhancement is generally observed. Non-stabilized, non-heated albumin is, however, vastly superior to "conventional", i.e. stabilized and pasteurized, albumin, presumably because of a greatly increased ability to form GTPD-Albumin as a result of greater biological competence. Even at extreme dilution, an approximately 6 log kill was found. At lower dilutions (higher concentrations of GTPD) the kill was apparently complete, probably 7 to 9 logs. It has also been found that the deactivation of anti-viral power of GTPD by lipoproteins and/or fatty acids is eliminated or greatly reduced by adding the GTPD as GTPD-Albumin. The ability of albumin to (a) bind GTPD, (b) not reduce and generally to enhance the viral inactivation power of GTPD, and (c) eliminate at low concentrations or greatly reduce any tendency of GTPD to hemolyze red blood cells is of enormous import. These results mean that GTPD can be carried into the system via albumin without losing its viral inhibition power, can be used at much higher concentrations than would otherwise be possible, and can be used where hemolysis is unacceptable. As reported in the prior art, it is known that GTPD will bind to albumin. The nature of the binding, which results in GTPD-Albumin, is not fully understood. GTPD bound to albumin would be expected to be less active chemically and biologically. Quite surprisingly, however, it was found that the viral inactivation characteristics of GTPD bound to albumin were not only not decreased but were, in some instances at least, enhanced. Perhaps the most interesting discovery, however, was that the tendency of GTPD to lyse erythrocytes at high concentrations of GTPD in blood or packed red blood cells was greatly reduced. At lower concentrations, GTPD, alone, actually stabilized red blood cells but at higher concentrations, GTPD tended to lyse red blood cells. This made it necessary to work with GTPD concentrations in blood and blood products within a fairly narrow range. GTPD can, however, be added to blood as GTPD-Albumin at two to five times the concentration which would lyse cells if the GTPD had been added alone with no discemable lysing of RBC. This permits the use of higher concentrations of GTPD, with more certainty of virus inactivation and less risk of lysing during mixing. GTPD-Albumin prepared from non-stabilized, non-heated albumin has even less tendency to hemolysis than GTPD-Albumin prepared from conventional albumin. Virus-inactivation by GTPD-Albumin from non-stabilized, non-heated albumin was also higher than that of GTPD- Albumin from conventional albumin. For example, a 5-6 log (complete) kill of vesicular stomatitis virus (VSV) in packed red blood cells was accom¬ plished by adding GTPD-Albumin solution to give a GTPD concentration of 0.5 % carbenoxolone and 10 % albumin after a wait period of one hour at 45°C without significant hemolysis. There is no criticality as to the ratio of GTPD and albumin. Generally, however, albumin will be present, on a weight percent basis, in ratio of from about 5:1 to 100:1, or more. For example, GTPD will generally be in the concentration range of about 0.05 to about 3 w/% in the blood product and albumin will be in the concentration range of from about 0.25 wt/% to 15 wt %. It is convenient to prepare a near saturate solution of albumin and add the maximum load of GTPD which the solution will carry as GTPD-Albumin and dilute the solution as desired. In carrying out this method, conventional blood collection containers may be used. Such containers are typically made of sterile polymer film and contain an anticoagulant. The collection, handling and administration of the blood by transfusion is the same as is conventionally carried out, save only for the processes involving preparation of the blood to containing the GTPD compounds in mixture with albumin. The GTPD-albumin compositions of this invention may be added to conventional anticoagulants, e.g. citrate dextrose, citrate phosphate dextrose, EDTA, heparin, etc. to enhance the anticoagulant effect of these, or to replace, in whole or in part, such anticoagulants. There is no criticality respecting the addition of GTPD-albumin compositions at the time of collection, as, for example, introducing blood into bags containing GTPD-albumin compositions, though there are some advantages of convenience in this approach and this approach reduces the risk to blood handlers after collection. GTPD-albumin compositions may be added after collection any time in the chain of handling the blood. It may be desirable to assure a satisfactory inactivation of pathogenic virus in blood to add GTPD-albumin compositions at two or more stages, such as at the time of collection and 24 or 48 hours later, or at any later time. If the blood is to be used for immediate transfusion, however, one careful thorough intermixing of a higher concentration of GTPD-albumin compositions with a shorter delay between collection and transfusion than would normally occur in the routine handling of blood. Glycerol and EDTA, most especially glycerol, in combination with GTPD as described gives an unpredicted and unexpected synergism. Glycerol in low concentrations is not an effective anti-viral agent, though at very high concentrations of glycerol, as is true of most hydroxy compounds, may in some instances inactivate some virus. Glycerol plus GTPD when present in concentrations much lower than would provide anything akin to complete viral inactivation with glycerol alone enhances the viral inactivation power of the GTPD by at least one log and in some instances by three logs or more. The optimum viral inactivator. combination, as presently understood, comprises glycyrrhizic triterpenoid compounds in an amount of from 0.005 to 10 wt % , preferably from about 0.1 to about 3 wt/ % and a viral inactivator enhancer, e.g. fatty acid in a concentration of from approximately 0.0001 to 0.5 wt/% of the blood product mixture and preferably a concentration of from approximately 0.0001 to 0.1 wt % of the blood product mixture. While other enhancers have not been studied to the extent that glycerol has been, and specific data are still being accumulated, a synergistic amount of 3'-azido-3'-deoxythymidine, dextran, butyl hydroxy toluene, fatty acid or ethylene diamine tetraacetic acid and salts thereof, as well as glycerol, in a concentration of from approximately 0.0001 to 0.5 wt/% of the of the blood mixture, and preferably in a concentration of from approximately 0.0001 to 0.1 wt/% of the blood product mixture are considered, on the basis of available information and data, to be effective. The invention is also embodied in a container for collecting, treating, storing, handling or preparing whole human blood or transfusion blood product for transfusion containing, as a part of the container, either in the main container or in a compartment of a multiple compartment container, one or more glycyrrhizic triterpenoid compounds in a concentration of from 0.05 to 10.0 wt/%, preferably from about 0.5 to about 3 wt/% and a viral inactivator enhancer, e.g. glycerol or EDTA, or both,, based on blood, sufficient to substantially inactivate virus in a blood product when the container is filled with such product. l-MRC-5 cells (Bartels) were grown in FCS and Eagle's minimal essential medium with 50 μg/ml of gentamicin, as the starting cell medium. 2-Cytomegalovirus [ATCC; 10 7 tissue culture infectious dose (50)] was added to three samples each of (a) the media, (b) blood A and (c) blood B. Glycyrrhizin in DMSO was added to one of the (a), (b) and (c) samples to a final concentration of 2 wt/%. Controls containing only media added to the same volume and DMSO in media were prepared. Six-hundred fold dilutions were used to infect MRC-% monolayers grown in glass coverslips inside glass vials. The inoculum was centrifiiged at l.OOOXg for 1 hr. at room tempera¬ ture, and 1 ml of fresh media was added to each vial. The cultures were incubated at 37°C. and observed daily for cytopathic effect. Seven-days post- infection the monolayers were fixed with methanol and stained by indirect fluorescent method using a CMV monoclonal antibody (Syva). No cytopathic effect was observed in the samples in which glycyrrhizin was present, while 3-4+ cytopathic effect was observed in the other samples. The fluorescent antibody technique showed no evidence of residual virus in blood treated with GTPD. Blood mixed with DMSO, and blood in media, tended to clot. Blood mixed with the glycyrrhizic compound did not clot, but slight hemolysis may have occurred. pH adjustments using KOH or NaOH, etc., may be required. Of the readily available GTPD compounds, carbenoxolone is preferred for its anti-viral effectiveness; however, glycyrrhizin and cicloxolone, in particular, and other GTPD compounds may be used with various advantages depending upon the particular compound. When GTPDs are added to whole human blood containing substantial amounts of lipids and lipoproteins the GTPD's are, over a period of time, absorbed or adsorbed or otherwise removed from solution as active com¬ pounds. The GTPD compounds when added as GTPD-Albumin, however, remain in the blood as effective viral inactivators for a much longer period of time, as compared with GTPD added alone. The GTPD compounds may be used to form GTPD-Albumin in their acid form; however, it is always necessary to check the pH after adding the GTPD compound and, if necessary, adjust the pH to about 7.0 - 8.0, e.g. with NaOH or KOH, before using the blood, as certain acid form GTPD compounds drop the pH of blood and plasma significantly to the pH 4-5 range. The acid form of the GTPD compounds is only slightly soluble in water but is quite soluble in dimethyl sulfoxide. The salt, e.g. ammonium, sodium or potassium salts, of the GTPD compounds are, generally, soluble in water, the sodium and potassium salts being more soluble than the ammonium salts. It is, thus, convenient to purchase or prepare the GTPD compounds as sodium or potassium salts. The effectiveness of GTPD compounds in killing or inactivating virus has been verified in fetal bovine serum (FBS) where additions glycyrrhetinic acid in concentrations of 0.05 to 0.7 percent followed by adjustment to pH 6.5 and 7.4, respectively for various trials, established a 100% kill of the relatively resistant vesicular stomatitis virus (VSV) was accomplished in all cases. The invention is embodied in an article of commerce comprising packaged transfusion blood in a container of whole human blood containing one or more glycyrrhizic triterpenoid compounds in an amount of from 0.001 to 10 wt %, preferably from about 0.05 to about 3 wt/%, in the form of GTPD-Albumin. The invention is also embodied in a method of preparing whole human blood or blood products for transfusion, comprising mixing such blood with one or more glycyrrhizic triterpenoid compounds, as GTPD-Albumin, in a concentration of from 0.05 to 10.0 wt/% , preferably from about 0.5 to about 3 wt/%, based on blood, sufficient to substantially inactivate at least CMV. As a method of treating a patient, the invention is a process compris- ing transfusing the patient with blood comprising one or more glycyrrhizic triterpenoid compounds, as GTPD-Albumin, in a concentration of from 0.05 to 10.0 wt %, preferably from about 0.5 to about 3 wt/%, based on blood, sufficient to substantially inactivate at least CMV. As a method of collecting blood the invention is embodied in a process comprising introducing said blood into a transfusion blood container containing glycyrrhizic triterpenoid, as GTPD-Albumin, compound sufficient to comprise from 0.05 to 10 wt/%, preferably from about 0.5 to about 3 wt % of the contents when the container is full. The invention is also embodied in blood products resulting from the treatment of blood with GTPD-albumin compositions. Such derivatives may include, for example, platelet and leukocyte concentrates, plasma, plasma derivatives such as, for example, cryoprecipitate, panels of red blood cells used in blood typing, and blood or blood fractions used for blood analysis such as, for example, the traditional blood samples now routinely collected in vacuum tubes. In such applications, the GTPD-albumin compositions may be present in or added to the vacuum tubes or at any later stage, though there are significant advantages in using vacuum tubes containing GTPD-albumin compositions. Donor blood may be processed to yield following single- donor components. Multiple donor pools of plasma harvested from whole blood can be processed to yield derivatives such as albumin, plasma protein fraction, Factor Vm concentrate, immune serum globulin preparation and concentrates of other blood factors. GTPD-albumin compositions may with great advantage be added along with glycerol or glycerol-water before freezing blood factors or derivatives to obtain a synergistic stabilizing effect, namely the stabilizing of GTPD by glycerol and the stabilizing of the blood factor or derivative, or whole blood in preparing cryoprecipitate, by both glycerol and the GTPD compound(s). GTPD-albumin compositions may be used in cell wash solutions to stabilize blood cells, platelets and the like, and to prevent or inhibit coagulation of the cells. It is advantageous, regardless of the mode or purpose in processing blood, to inactivate pathogenic virus at the earliest reasonable stage in the handling chain and/or at specific points in the handling chain. The present invention is well adapted to any blood processing regime. In all embodiments, the invention exhibits a number of surprising results. The spotty results reported in efforts to determine if, and to what extent, GTPD compositions are indeed virucidal agents led the art to believe, as has been reported, that "the likelihood of developing a blood additive that would kill HIV and HBV and have no effect on laboratory examination of blood seems small." (Peter C. Fuchs, M.L.O., Oct. 1988, 13). In addition, notwithstanding the prior art in which anti-viral activity, to the extent it exists, of GTPD compounds is uncertain, unpredictable and, as yet, unexplained, and the widely accepted proposition that no blood additive could be found which would inactivate blood-borne viruses without adversely effecting the blood, e.g. lysing the red blood cells and/or interfering with blood analyses, the present invention embodies processes and blood compositions in which these desired but hitherto unattainable results are accomplished with enhanced certainty and reduced risk of damage to blood cells. The GTPD-albumin compositions can be mixed with other active compounds with synergistic results in inactivation of virus. Such synergistic and potentially synergistic compounds include glycerol, the anti-viral drug AZT, which is known to act synergistically with the GTPD compounds, dextrans, butyl hydroxy toluene, fatty acids such as oleic acid, chelating agents such as EDTA, and compounds of transition and heavy metals. In the case of blood, plasma or other fluid collection in a bag, vacuum tube, vial or other container, a highly desirable and preferred method and apparatus are utilized. The GTPD-Albumin is in or associated with the container. Industrial Application This invention has direct application in the blood banking industry and in the production of transfusion blood products from transfusion quality blood.

Claims: WHAT IS CLAIMED: 1. A transfusion blood container for the introduction of one or more blood products, comprising: a) a transfusion blood container; and b) an amount of one or more glycyrrhizic triterpenoid compounds sufficient to comprise from 0.05 to 10.0 wt/% of the contents of the container when full of the blood product, sufficient to substantially inactivate viruses contained in the blood product introduced into said container. 2. The transfusion blood container of Claim 1 further comprising albumin in combination with said glycyrrhizic triterpenoid compounds, albumin in an amount of from about five to about one hundred times the amount of glycyrrhizic triterpenoid compounds. 3. The transfusion blood container of Claim 1 further comprising glycerol in a concentration of from approximately 0.0001 to 5 wt/% based on blood product. 4. The transfusion blood container of Claim 1 further comprising ethylene diamine tetraacetic acid and/or salts thereof in a concentration of from approximately 0.0001 to 5 wt/% based on blood product. 5. The transfusion blood container of Claim 1 further comprising a synergistic amount of 3'-azido-3'-deoxythymidine, dextran, butyl hydroxy toluene, or fatty acid is present in a concentration of from approximately 0.0001 to 0.1 wt % of the blood product when the container is full. 6. The transfusion blood container of Claim 1 wherein said blood product consists essentially of one or more of the following: whole blood, platelet concentrations, leukocyte concentrations, plasma, plasma derivatives, and whole blood fractions. 7. The transfusion blood container of Claim 6 further comprising albumin in combination with said glycyrrhizic triterpenoid compounds, albumin in an amount of from about five to about one hundred times the amount of glycyrrhizic triterpenoid compounds. 8. The transfusion blood container of Claim 6 further comprising glycerol in a concentration of from approximately 0.0001 to 5 wt % based on blood product. 9. The transfusion blood container of Claim 6 further comprising ethylene diamine tetraacetic acid and/or salts thereof in a concentration of from approximately 0.0001 to 5 wt/% based on blood product. 10. The transfusion blood container of Claim 6 further comprising a synergistic amount of 3'-azido-3'-deoxythymidine, dextran, butyl hydroxy toluene, or fatty acid in a concentration of from approximately 0.0001 to 0.1 wt/% of the blood product when the container is full. 11. Transfusion blood product comprising a transfusion container of human blood product containing one or more glycyrrhizic triterpenoid compounds in an amount of from 0.005 to 10 wt % effective to substantially inactivate susceptible viruses therein. 12. The transfusion blood product of Claim 11 further comprising albumin in combination with said glycyrrhizic triterpenoid compounds, albumin in an amount of from about five to about one hundred times the amount of glycyrrhizic triterpenoid compounds. 13. The transfusion blood product of Claim 11 further comprising glycerol in a concentration of from approximately 0.0001 to 5 wt/% based on blood product. 14. The transfusion blood product of Claim 11 further comprising ethylene diamine tetraacetic acid and/or salts thereof in a concen¬ tration of from approximately 0.0001 to 5 wt/% based on blood product. 15. The transfusion blood product of Claim 11 further comprising a synergistic amount of 3'-azido-3'-deoxythymidine, dextran, butyl hydroxy toluene, or fatty acid in a concentration of from approximate¬ ly 0.0001 to 0.1 wt/% based on blood product. 16. The transfusion blood product of Claim 11 wherein said blood product consists essentially of one or more of the following: whole blood, platelet concentrations, leukocyte concentrations, plasma, plasma derivatives, and whole blood fractions. 17. The transfusion blood product of Claim 16 further comprising albumin in combination with said glycyrrhizic triterpenoid compounds, albumin in an amount of from about five to about one hundred times the amount of glycyrrhizic triterpenoid compounds. 18. The transfusion blood product of Claim 16 further comprising glycerol in a concentration of from approximately 0.0001 to 5 wt/% based on blood product. 19. The transfusion blood product of Claim 16 further comprising ethylene diamine tetraacetic acid and/or salts thereof in a concen¬ tration of from approximately 0.0001 to 5 wt/% based on blood product. 20. The transfusion blood product of Claim 16 further comprising a synergistic amount of 3'-azido-3'-deoxythymidine, dextran, butyl hydroxy toluene, or fatty acid in a concentration of from approximate¬ ly 0.0001 to 0.1 wt/% based on blood product. 21. A method for preparing human blood product for transfusion, comprising mixing such blood product with one or more glycyrrhizic triterpenoid compounds in a concentration of from 0.05 to 10.0 wt/% based on blood product and holding the resulting mixture for a period of at least about one hour, the concentration being sufficient to substantially inactivate susceptible viruses found in animal fluids and tissues within said time. 22. The method of Claim 21 further comprising adding an additional amount of said glycyrrhizic triterpenoid compounds into such blood product approximately at or after the end of the first holding period to renew the concentration thereof to from about 0.1 to about 3 wt/% and holding the resulting mixture for a second holding period of at least about 12 hours. 23. The method of Claim 21 further comprising adding albumin in combination with said glycyrrhizic triterpenoid compounds, albumin in an amount of from about five to about one hundred times the amount of glycyrrhizic triterpenoid compounds. 24. The method of Claim 21 further comprising adding glycerol in a concentration of from approximately 0.0001 to 5 wt/% based on blood product. 25. The method of Claim 21 further comprising adding ethylene diamine tetraacetic acid and/or salts thereof in a concentration of from approximately 0.0001 to 5 wt/% based on blood product. 26. The method of Claim 21 further comprising adding a synergistic amount of 3'-azido-3'-deoxythymidine, dextran, butyl hydroxy toluene, or fatty acid in a concentration of from approximately 0.0001 to 0.1 wt/% based on blood product. 27. The method of any of Claims 21, 22, 23, 24, 25 or 26 further comprising the step of maintaining the temperature of the blood product at from about 37°C. + about 8°C. for form about one to twenty four hours after the blood product and the glycyrrhizic triterpenoid compound are mixed. 28. The method of Claim 23 wherein the albumin is delipidated before being mixed with the glycyrrhizic triterpenoid compound. 29. The method of Claim 23 wherein the albumin and the glycyrrhizic triterpenoid compound are mixed before being added to the blood product by mixing albumin from the patient to receive the blood product with the glycyrrhizic triterpenoid compound. 30. The blood product container of Claim 2 or Claim 7 wherein the albumin is delipidated before being mixed with the glycyrrhizic triterpenoid compound. 31. The blood product of Claim 12 or Claim 17 wherein the albumin is delipidated before being mixed with the glycyrrhizic triterpenoid compound.

Inventors: SHANBROM EDWARD, SHANBROM, EDWARD
Applicants: SHANBROM EDWARD, SHANBROM, EDWARD
Application year: 1989
Main classification: A61L2
IPC codes: A61K35, A61K38, A61L2, A61P7, C07H15